

University of Texas Rio Grande Valley
ScholarWorks @ UTRGV

Biology Faculty Publications and Presentations

College of Sciences

9-1-2014

Two Roads Converging: Mitochondria and Inflammatory Signaling

Robert Gilkerson

The University of Texas Rio Grande Valley

Luis Materon

The University of Texas Rio Grande Valley

Follow this and additional works at: https://scholarworks.utrgv.edu/bio_fac

 Part of the [Biology Commons](#)

Recommended Citation

Gilkerson, R., & Materon, L. (2014). Two Roads Converging: Mitochondria and Inflammatory Signaling. *Journal of Clinical Immunology & Immunotherapy*, 1(1), 1–7. <https://doi.org/10.24966/CIIT-8844/100004>

This Article is brought to you for free and open access by the College of Sciences at ScholarWorks @ UTRGV. It has been accepted for inclusion in Biology Faculty Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu, william.flores01@utrgv.edu.



Review Article

Two Roads Converging: Mitochondria and Inflammatory Signaling

Robert Gilkerson^{1,2} and Luis Materon^{1*}

¹Departments of Biology, University of Texas RGV, 1201 West University Drive, Edinburg, TX 78539, USA

²Clinical Laboratory Sciences, University of Texas RGV, 1201 West University Drive, Edinburg, TX 78539, USA

Abstract

As the complexity of cellular signaling in inflammatory response emerges, it is increasingly clear that mitochondria are directly involved in, and in some cases are even required for, activation of inflammatory response. As a bioenergetic organellar network, mitochondria dynamically modulate their organization and function in response to cellular signaling cues and metabolic demand. The NLRP3 inflammasome, a caspase-activating multifactor scaffolding assembly, is directly activated by mitochondrial factors and functional parameters. Mitochondria are also heavily implicated as downstream targets of inflammation in a variety of tissues. Elevated inflammation and cytokine-mediated damage to mitochondria are implicated in the pathogenesis of disparate conditions such as Type 2 diabetes and autism spectrum disorders. Recent findings indicate that mitochondrial factors are released as extracellular mediators of inflammatory response. Here, we discuss the mechanistic interaction of mitochondria in inflammatory signaling, as well as the implications for inflammatory mitochondrial damage as a causative force in highly prevalent human diseases.

Inflammatory Signaling and Innate Immune Response

Inflammation is a crucial mechanism of innate immune response. Macrophages and neutrophils recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), undergoing a complex set of signaling interactions to release pro-inflammatory cytokines (most notably IL-1 β and IL-18 [1] that prompt inflammatory response. To mediate innate immune response, pattern-recognition receptors (PRRs) recognize a broad range of markers of infection, stress, and damage. PRRs include membrane-bound receptors such as Toll-like receptors (TLRs), the interleukin receptors (ILRs), and the tumor necrosis factor receptors 1 (TNF-R1) and 2 (TNF-R2). Upon

*Corresponding author: Luis Materon, Departments of Biology, University of Texas- Pan American, 1201 West University Drive, Edinburg, TX 78539, USA, Tel: 956-665-7140; Fax: 956-665-3657; E-mail: lmateron@utpa.edu

Citation: Gilkerson R, Materon L (2014) Two Roads Converging: Mitochondria and Inflammatory Signaling. J Clin Immunol Immunother 1: 004.

Received: July 11, 2014; Accepted: August 18 2014; Published: September 01, 2014

binding of extracellular ligands, these PRRs activate intracellular signaling events, such as activation of NF κ B, a transcription factor that upregulates expression of a wide variety of stress-response genes, or through post-translational modification such as activation of c-Jun amino-terminal kinase (JNK) [2] to effect inflammatory response. Within the cytoplasm, inflammatory ligands bind and activate intracellular PRRs that combine with a variety of associated factors to form large cytoplasmic scaffolding assemblies that integrate inflammatory activation and activate secretion of the major cytokines IL-1 β and IL-18 by binding and activating caspase-1 [3] (Figure 1). These cytoplasmic PRRs, classed as nucleotide-binding domain leucine-rich repeat-containing receptors (NLRs), recognize a wide variety of intracellular inflammatory stimuli. Four classes of NLRs (NLRP1, NLRP3, NLRC4 and AIM2) share in common a nucleotide-binding oligomerization domain, and have demonstrated an ability to form large oligomeric inflammasome complexes in the cytoplasm [4]. While each of the four sense a variety of inflammatory signals to mediate caspase-dependent activation of inflammation, the NLRP3 inflammasome is the best characterized.




Figure 1: Schematic of mitochondrial interactions with NLRP3 inflammasome signaling.

Plasma membrane PRRs TLR, ILR, and TNF-R (red boxes) bind cytokines and extracellular ligands, activating NF κ B and JNK, which activate nuclear transcription of cellular stress factors, particularly NLRP3. NLRP3 (blue), ASC (gold), and caspase-1 (purple) associate in the cytoplasm as the large, macromolecular NLRP3 inflammasome in macrophages. Mitochondria are impacted by membrane-bound PRR signals and aid in activating the NLRP3 inflammasome (via

ROS or specific interaction with mtDNA, cardiolipin, MFN2, or MAVS). Inflammasome activation results in cleavage of pro-IL-1 β and pro-IL-18 to active cytokines IL-1 β and IL-18, which are secreted from the cell to spread inflammation.

The NLRP3 Inflammasome

The NACHT, LRR, and PYD domain-containing protein (NLRP3) is a major mediator of caspase-1 activation. To accomplish this, NLRP3 associates with the apoptosis-associated speck-like protein containing a CARD domain (ASC) adaptor protein. ASC contains a caspase recruitment domain (CARD), thus allowing binding of pro-caspase-1 to the inflammasome complex. ASC has a remarkable ability to dimerize and associate with pro-caspase-1, causing formation of a single large (~2 μ m diameter) NLRP3 inflammasome in macrophages [5].

Formation of the NLRP3 inflammasome is cued by the membrane-bound PRRs, such as the TLRs, ILRs, and TNF-Rs, which activate NF κ B and JNK in the nucleus. NF κ B is a major stress-response transcription factor, which rapidly increases mRNA levels of pro-inflammatory factors, particularly NLRP3 and pro-IL-1 β [6,7]. For inflammasome formation, NF κ B-mediated increases in transcription of both NLRP3 and pro-IL-1 β are required, as these factors are found at low basal levels. Conversely, ASC and pro-caspase-1 (as well as pro-IL-18) are found at sufficiently high levels in the cytoplasm to allow inflammasome assembly [6]. Upon binding of caspase-1 as part of the NLRP3 inflammasome, the inactive pro-caspase-1 is autocatalytically cleaved and forms the active caspase-1 heterodimer [8,9]. Active caspase-1 then cleaves pro-IL-1 β and pro-IL-18 to their active IL-1 β and IL-18 forms, which are then secreted as inflammatory cytokines [8-10] (Figure 1). An exciting collection of findings indicates that a variety of factors located in the mitochondria play a crucial role in NLRP3 inflammasome response.

Mitochondria: A Dynamic Organellar Network

As organelles of endosymbiotic origin [11], mitochondria occupy a highly unique niche in cellular biology. By combining genetic contributions from both chromosomal and mitochondrial genomes, mitochondria carry out the bulk of cellular ATP production via oxidative phosphorylation. Mitochondrial structure is incredibly dynamic, changing in response to cellular need and organellar bioenergetic function, even in cells with highly constrained architecture such as cardiac [12] and skeletal muscle fibers [13]. This dynamic structure undergoes profound alteration in response to mitochondrial dysfunction, indicating that structural dynamics represent a critical parameter to be explored in mitochondrial-immune interactions.

The dual genetic composition of mitochondria is unique among the organelles of a human cell: both nuclear- and mitochondrially-encoded gene products are required to fully assemble the five complexes of oxidative phosphorylation (OxPhos) in the mitochondrial inner membrane. While hundreds of proteins are present in human mitochondria [14,15], the vast majority of these are encoded by nuclear genes. Mitochondrial DNA (mtDNA) encodes only 2 rRNAs, 22 tRNAs, and 13 polypeptides from a 16,569 bp circular DNA. Despite the small handful of proteins encoded by mtDNA, these polypeptides are essential subunits of the OxPhos complexes in the inner membrane. While Complex II is encoded solely by nuclear DNA, the other four complexes each contain at least one mtDNA-encoded polypeptide. Complexes I-IV transfer electrons

supplied by NADH and FADH₂, ultimately donated to molecular oxygen to create water, to drive H⁺ pumping from the mitochondrial matrix to the intermembrane space. This H⁺ pumping activity generates a proton-motive force, which in higher organisms is chiefly comprised of an electrochemical gradient, or transmembrane potential ($\Delta\psi_m$) that is then utilized by the F₁F₀ ATP synthase [16]. By allowing a single H⁺ to return to the matrix down the gradient, ADP and P_i are bound at the F₁ portion of the ATP synthase and coalesced to ATP during the rotation-mediated conformational shifting of the holoenzyme [17].

Mitochondrial structure is organized to support bioenergetic function. While traditional models of mitochondrial ultrastructure envisioned a collection of individual organelles dispersed throughout the cytoplasm, advances in cellular imaging and the identification of genetic factors controlling mitochondrial morphology have combined to reveal mitochondrial ultrastructure as a highly dynamic, sensitive process capable of dramatic response to cellular stimuli. Mitochondria were originally named as being 'thread-like granules.' Improved imaging techniques revealed that mitochondria do in fact have the ability to interconnect as a networked reticulum throughout the cell [12,18]. Optic atrophy 1 (OPA1) was identified as a factor that is required for fusion of the mitochondrial inner membrane [19], while mitofusin 1 (MFN1) and mitofusin 2 (MFN2) carry out fusion of the outer mitochondrial membrane (Hoppins et al., 2007). While OPA1, MFN1, and MFN2 carry out mitochondrial fusion, a different set of factors carry out mitochondrial fission. FIS1 [20] and MFF [21] are mitochondrial outer membrane proteins that recruit dynamin-related protein 1 (DRP1) from the cytoplasm. Upon docking at the outer membrane, DRP1 will form multimeric rings around a mitochondrion, dividing it in two [23]. Thus, mitochondrial fusion and fission are opposing processes governed by different sets of factors, in which a cell will balance mitochondrial organization between the two (Figure 2).




Figure 2: 3T3 mouse embryonic fibroblasts visualized by confocal fluorescence microscopy, labeled for mitochondria (MitoTracker, red) and the nucleus (DAPI, blue).

The cell's mitochondria display both interconnected, fused mitochondria (to the right of the nucleus) and fragmented, divided mitochondria (to the left of the nucleus). Size bar = 10 μm .

Mitochondrial ultrastructure is directly tied to mitochondrial function, existing in a sensitive balance to maintain energetic homeostasis. Damage or dysfunction to the structure/function balance of mitochondria causes a loss of ability to maintain a fused, interconnected mitochondrial network. Cells with either genetic [23] or pharmacologically-induced mitochondrial dysfunction [24] have mitochondria that are unable to fuse together, instead maintaining an obligately fragmented organization. This loss of organellar fusion under conditions of mitochondrial dysfunction is caused by proteolytic cleavage of the OPA1 fusion protein [25], occurring when the $\Delta\psi_m$ across the mitochondrial inner membrane is low [26]. Subsequently, $\Delta\psi_m$ -sensitive cleavage of OPA1 was found to be mediated by OMA1, a metalloprotease located in the inner mitochondrial membrane [27,28]. Thus, mitochondrial function (specifically $\Delta\psi_m$) directly mediates mitochondrial fusion by OPA1, while transgenic ablation of either mitochondrial fission [29] or fusion [30] negatively impacts bioenergetic function, indicating the hand-in-hand relationship between mitochondrial bioenergetic function and structural organization. Moreover, while bioenergetic dysfunction and loss of efficient mitochondrial organization are detrimental in and of themselves, emerging evidence suggests that mitochondrial dysfunction plays a strong role in activation of NLRP3-mediated inflammatory signaling (discussed below). As mitochondrial structural dynamics are directly linked to processes including apoptosis and autophagy [31,32], mitochondrial-inflammatory interactions are likely to be similarly linked to a fascinating set of dynamic alterations, with enormous consequences for the cell and surrounding environment.

Mitochondria in NLRP3 Inflammasome Signaling

Mitochondria are emerging as a major activator of NLRP3 inflammasome signaling, and are in some cases required for NLRP3 inflammasome activation. Recent findings show that a variety of mitochondrial components interacts with and activate the NLRP3 inflammasome as major contributors to innate immune signaling by macrophages. Even more intriguingly, Misawa et al. showed that mitochondria are recruited *en masse* to the inflammasome within the cytoplasm of macrophages [33], suggesting that a host of other mitochondrial factors may have critical roles in inflammasome-mediated signaling.

A role for mitochondria in NLRP3 inflammasome signaling was first suggested when mitochondria were observed to colocalize with the NLRP3/ASC/caspase-1 scaffold assembly upon inflammasome induction. While reactive oxygen species (ROS) had previously been shown to be necessary for NLRP3 inflammasome activity [34], inhibition of the mitochondrial voltage-dependent anion channel (VDAC) abrogated both intracellular ROS levels and inflammasome assembly, indicating that mitochondrial ROS production is directly involved in NLRP3 inflammasome signaling of macrophages [35]. Subsequently, macrophages treated with *E. coli* lipopolysaccharide or ATP (both inflammasome activators) displayed release of mtDNA into the cytoplasm. Moreover, transfection to deliver cytoplasmic mtDNA stimulated secretion of both IL-1 β and IL-18, indicating that release of mtDNA from the mitochondrial matrix into the surrounding cytoplasm directly contributes to NLRP3 inflammasome activity. Shimada et al. [36] then found that mitochondrial dysfunction

correlates with NLRP3 inflammasome activity, with binding of oxidized mtDNA a required step in NLRP3 inflammasome activation and IL-1 β [36]. These results provide an unusual mechanism of inflammasome activation: while mtDNA damage is increasingly appearing as a common form of mitochondrial damage in a variety of cellular settings [37,38], it is unclear how a highly packaged, compacted circle of DNA [39,40] is released from a double membrane-bound organelle into the cytoplasm. Future research will undoubtedly shed new light on how mtDNA escapes the organelle to participate in inflammatory signaling.

Additional studies suggest that entire mitochondrial organelles are active players in NLRP3 inflammasome activity. Cardiolipin, a diphosphatidylglycerol lipid, is found nearly exclusively in the mitochondrial inner membrane. However, upon both ROS-dependent and -independent induction of the NLRP3 inflammasome, cardiolipin translocates to the outer membrane of the mitochondria, where it interacts with the leucine-rich repeat (LRR) domain of NLRP3, concurrent with ASC and caspase-1 recruitment to the inflammasome leading to IL-1 β secretion [41]. Cardiolipin translocation to the outer membrane appears to be mediated by phospholipid scramblase-3, contributing to mitochondrial autophagy in rat cortical neurons [42], suggesting that binding of cardiolipin by cytoplasmic signaling molecules is a general stress-response mechanism in cells, with profound disease implications. As a large-scale cytoplasmic macromolecular scaffolding assembly, the NLRP3 inflammasome requires the tubulin cytoskeleton to transport mitochondria to inflammasome sites, where they bind to ASC [33]. The mitochondrial anti-viral signaling (MAVS) factor is a likely adaptor protein mediating NLRP3-mitochondrial interaction, required for IL-1 β maturation and secretion in THC-1 monocytes, as well as macrophages [43,44]. MFN2 is required for NLRP3 inflammasome activation following infection with RNA virus: Ichinohe et al. found that this association requires an intact $\Delta\psi_m$ for MFN2-NLRP3 interaction [45]. These studies indicate that a diverse set of mitochondrial factors mediate activation of the NLRP3 inflammasome (Figure 1). MFN2 and MAVS, as proteins located in the outer mitochondrial membrane, are easier to envision as 'docking partners' with the NLRP3 protein, while translocation of cardiolipin to the mitochondrial outer membrane and the release of mtDNA from the organelle into the cytoplasm represent highly dynamic events in inflammasome activation. These studies clearly demonstrate that much remains to be understood regarding the roles these factors play in inflammatory response, and further indicate that additional mitochondrial factors localized to any part of the organelle may be similarly involved in dynamic recruitment to the NLRP3 inflammasome. Further, the studies above (except where indicated) have characterized NLRP3 signaling interactions in macrophages, as major mediators of innate immune response. It is highly likely that NLRP3-mediated signaling will show a range of specific responses in different cell types throughout the body.

Inflammatory Damage to Mitochondria

In addition to their emerging role as integral contributors to inflammatory response in the innate immune system, mitochondria are increasingly implicated as cellular targets of cytokine-mediated inflammation in a host of tissues. While macrophages and similar immune cells involve mitochondria in inflammatory signaling, many of the same cytokines have been shown to damage mitochondria in the pathogenesis of prevalent human diseases, particularly Type 2 diabetes mellitus.

Mitochondria have long been implicated in the pathogenesis of Type 2 diabetes mellitus and associated metabolic disorders. Decreased mitochondrial function [46,47] and gene expression [48,49] have been strongly correlated with Type 2 diabetes in diverse tissues such as skeletal muscle and peripheral blood. As such, an abundance of clinical and experimental data indicates that decreased mitochondrial function and bioenergetics capacity plays a contributing role in Type 2 diabetes. However, it has been unclear what genetic or environmental factors this can be attributed to. Inherited mutations of mtDNA cause insulin resistance and diabetes mellitus in patients [50,51], indicating that mitochondrial dysfunction can be a causative determinant of insulin resistance. Despite this, inherited pathogenic mtDNA mutations do not occur frequently enough (1 in 5,000-10,000 individuals [52,53] to explain the rapidly-expanding prevalence of Type 2 diabetes worldwide. However, the emergence of cytokine-mediated inflammation as a causative mechanism of Type 2 diabetes suggests that cytokine-mediated damage to mitochondria plays a major role in the pathogenesis of diabetes and co-morbid conditions.

Cytokine-mediated inflammation has gained recognition as a major causative force in the development of insulin resistance and diabetes [54-56]. While the initial studies demonstrating this causative mechanism explored the ability of TNF- α to mediate insulin resistance [55], subsequent studies built upon these findings to include IL-1 β , IL-6, IL-18, resistin, leptin, adiponectin, and others. Many of these are expressed both by macrophages and adipocytes, providing a mechanistic link for the co-morbidity of Type 2 diabetes and obesity [57]. Upon binding of these cytokines to PRRs at the plasma membrane, the NF κ B and JNK pathways are activated, mediating crucial stress-mediated transcription of inflammatory factors (such as IL-1 β and NLRP3, above). The NLRP3 inflammasome is activated in cytokine-mediated insulin resistance [58,59] and mediates impaired wound healing through sustained inflammation in diabetic patients [60].

Many of these same cytokines have been shown to directly damage mitochondria. TNF- α cause rapid damage to mtDNA and increased ROS production [61], and inhibits mitochondrial bioenergetics [62]. This TNF- α -induced damage is dependent on TNF-R1 binding, and appears to involve stress-response translocation of p53 to mitochondria [61,63]. Similarly, heat-inactivated *E. coli* activates TLR-4, causing mtDNA depletion [64]. These findings are concordant with experimental and clinical data showing loss of mtDNA content and bioenergetic function [65-67]. This mitochondrial damage has wide-ranging effects on the cell at large. Mitochondrial involvement in the development of insulin resistance appears to occur via elevated mitochondrial ROS production, rather than decreased OxPhos activity *per se* [68]. Mitochondrial dysfunction has been suggested to cause insulin resistance by decreasing insulin receptor substrate-1 (IRS1) expression [69,70]. Mechanistically, loss of mtDNA has been shown to effect broad changes in nuclear transcription via 'retrograde' mitochondria-to-nucleus signaling, in which mitochondrial dysfunction affects pathways including NF κ B and JNK to add to cellular stress response [71,72]. The specific impacts of mitochondrial dysfunction on gene expression of various inflammatory factors are likely to provide insight into a critical cell-wide consequence of mitochondrial dysfunction.

While the connections between inflammatory signaling and mitochondria have been best characterized in diabetes and metabolic

disorders, these interactions are increasingly found across a range of other prevalent diseases. Gene expression profiling [73,74] and biomarker studies find increases in cytokines in autistic subjects [75], particularly IL-6 and TNF- α [76-]. These studies are consistent with findings of mitochondrial dysfunction and increased organellar fission in brain samples of autistic individuals [79]. Similar involvement of NLRP3-associated inflammation is found in Alzheimer's disease [80] and cardiomyopathy [81]. These associations strongly suggest that inflammation and mitochondria comprise a pathogenic axis that is likely to play a role in a wide range of prominent human diseases.

Mitochondrial Factors as Inflammatory Messengers

As discussed above, the release of mtDNA from the organelle in response to NLRP3-associated inflammatory stimuli is a highly novel, dynamic response, suggesting that mtDNA is a key mediator of intracellular inflammation. Recent evidence suggests that mtDNA and associated factors may have further roles as *extracellular* inflammatory mediators. Mathew et al. observed that extracellular, partially degraded mtDNA causes induction of cytokine secretion, most notably IL-1 β , suggesting that mtDNA is itself a category of damage-associated molecular pattern (DAMP) for recognition by PRRs [82]. Similarly, Chung et al. [83] found that transcription factor A, mitochondrial (TFAM), the major mtDNA-packaging protein, mediates inflammation in hemorrhagic shock [83]. These findings strongly indicate that mtDNA and the other protein factors directly associated with it [39] are released from mitochondria and act as pro-inflammatory signaling factors, appearing as clinically-relevant indicators of inflammation in experimental systems and patients [84,85]. Just as the adaptive nature of the mitochondrial network has become evident as a key element of cellular homeostasis, these findings indicate the importance of mitochondrial factors as mediators of inflammatory signaling. The mechanisms of mitochondrial factor release will reveal exciting, highly novel molecular dynamics of factors previously thought to reside exclusively within mitochondria.

Conclusion

The specific interactions of mitochondrial factors with innate inflammatory factors, particularly NLRP3, bring together two fields of cell biology that previously had little apparent connection. These interactions are of enormous importance medically, as increased inflammation has emerged as a causative or contributory factor in a wide range of many of the most rapidly-expanding diseases today. As the dynamics and causes of both bioenergetic stress and inflammation in human disease are uncovered, understanding the intrinsic mechanistic connections of inflammatory signaling with mitochondrial biology is increasingly vital to cellular homeostasis and human health.

Acknowledgements

This work is supported by a Research Grant from the Diabetes Action Research and Education Foundation (to RG).

References

1. Garlanda C1, Dinarello CA2, Mantovani A3 (2013) The interleukin-1 family: back to the future. *Immunity* 39: 1003-1018.
2. Nguyen MT1, Satoh H, Favelyukis S, Babendure JL, Imamura T, et al. (2005) JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. *J BiolChem* 280: 35361-35371.

3. Martinon F1, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. *Mol Cell* 10: 417-426.
4. Franchi L1, Eigenbrod T, Muñoz-Planillo R, Nuñez G (2009) The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. *Nat Immunol* 10: 241-247.
5. Fernandes-Alnemri T1, Wu J, Yu JW, Datta P, Miller B, et al. (2007) The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. *Cell Death Differ* 14: 1590-1604.
6. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, et al. (2009) NF-kB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. *J Immunol* 183:787-791.
7. Fitzgerald DC, Meade KG, McEvoy AN, Lillis L, Murphy EP, et al. (2007) Tumour necrosis factor-alpha (TNF-alpha) increases nuclear factor kappaB (NFkappaB) activity in and interleukin-8 (IL-8) release from bovine mammary epithelial cells. *Vet ImmunolImmunopathol* 116:59-68.
8. Thornberry NA1, Bull HG, Calaycay JR, Chapman KT, Howard AD, et al. (1992) A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. *Nature* 356: 768-774.
9. Wilson KP1, Black JA, Thomson JA, Kim EE, Griffith JP, et al. (1994) Structure and mechanism of interleukin-1 beta converting enzyme. *Nature* 370: 270-275.
10. Gu Y1, Kuida K, Tsutsui H, Ku G, Hsiao K, et al. (1997) Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. *Science* 275: 206-209.
11. Sagan L (1967) On the origin of mitosingcells *JTheor Biol* 14: 255-274.
12. Amchenkova AA1, Bakeeva LE, Chentsov YS, Skulachev VP, Zorov DB (1988) Coupling membranes as energy-transmitting cables. I. Filamentous mitochondria in fibroblasts and mitochondrial clusters in cardiomyocytes. *J Cell Biol* 107: 481-495.
13. Liu R1, Jin P2, LiqunYu2, Wang Y2, Han L2, et al. (2014) Impaired mitochondrial dynamics and bioenergetics in diabetic skeletal muscle. *PLoS One* 9: e92810.
14. Elstner M1, Andreoli C, Klopstock T, Meitinger T, Prokisch H (2009) The mitochondrial proteome database: MitoP2. *Methods Enzymol* 457: 3-20.
15. Taylor SW1, Fahy E, Zhang B, Glenn GM, Warnock DE, et al. (2003) Characterization of the human heart mitochondrial proteome. *Nat Biotechnol* 21: 281-286.
16. DiMauro S1, Schon EA (2003) Mitochondrial respiratory-chain diseases. *N Engl J Med* 348: 2656-2668.
17. Capaldi RA1, Aggeler R (2002) Mechanism of the F(1)F(0)-type ATP synthase, a biological rotary motor. *Trends BiochemSci* 27: 154-160.
18. Rizzuto R1, Pinton P, Carrington W, Fay FS, Fogarty KE, et al. (1998) Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. *Science* 280: 1763-1766.
19. Olichon A1, Baricault L, Gas N, Guillou E, Valette A, et al. (2003) Loss of OPA1 perturbs the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. *J BiolChem* 278: 7743-7746.
20. Yoon Y1, McNiven MA (2001) Mitochondrial division: New partners in membrane pinching. *CurrBiol* 11: R67-70.
21. Gandre-Babbe S1, van der Bliek AM (2008) The novel tail-anchored membrane protein Mff controls mitochondrial and peroxisomal fission in mammalian cells. *MolBiol Cell* 19: 2402-2412.
22. Hoppins S1, Lackner L, Nunnari J (2007) The machines that divide and fuse mitochondria. *Annu Rev Biochem* 76: 751-780.
23. Gilkerson RW1, Margineantu DH, Capaldi RA, Selker JM (2000) Mitochondrial DNA depletion causes morphological changes in the mitochondrial reticulum of cultured human cells. *FEBS Lett* 474: 1-4.
24. Legros F1, Lombès A, Frachon P, Rojo M (2002) Mitochondrial fusion in human cells is efficient, requires the inner membrane potential, and is mediated by mitofusins. *MolBiol Cell* 13: 4343-4354.
25. Griparic L1, Kanazawa T, van der Bliek AM (2007) Regulation of the mitochondrial dynamin-like protein Opa1 by proteolytic cleavage. *J Cell Biol* 178: 757-764.
26. Guillery O1, Malka F, Landes T, Guillou E, Blackstone C, et al. (2008) Metalloprotease-mediated OPA1 processing is modulated by the mitochondrial membrane potential. *Biol Cell* 100: 315-325.
27. Ehse S1, Raschke I, Mancuso G, Bernacchia A, Geimer S, et al. (2009) Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1. *J Cell Biol* 187: 1023-1036.
28. Head B1, Griparic L, Amiri M, Gandre-Babbe S, van der Bliek AM (2009) Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. *J Cell Biol* 187: 959-966.
29. Parone PA1, Da Cruz S, Tondera D, Mattenberger Y, James DI, et al. (2008) Preventing mitochondrial fission impairs mitochondrial function and leads to loss of mitochondrial DNA. *PLoS One* 3: e3257.
30. Chen H1, Chomyn A, Chan DC (2005) Disruption of fusion results in mitochondrial heterogeneity and dysfunction. *J BiolChem* 280: 26185-26192.
31. Nunnari J1, Suomalainen A (2012) Mitochondria: in sickness and in health. *Cell* 148: 1145-1159.
32. Tanner EA1, Blute TA, Brachmann CB, McCall K (2011) Bcl-2 proteins and autophagy regulate mitochondrial dynamics during programmed cell death in the *Drosophila* ovary. *Development* 138: 327-338.
33. Misawa T1, Takahama M, Kozaki T, Lee H, Zou J, et al. (2013) Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. *Nat Immunol* 14: 454-460.
34. Martinon F (2010) Signaling by ROS drives inflammasome activation. *Eur J Immunol* 40: 616-619.
35. Zhou R1, Yazdi AS, Menu P, Tschopp J (2011) A role for mitochondria in NLRP3 inflammasome activation. *Nature* 469: 221-225.
36. Shimada K1, Crother TR, Karlin J, Dagvadorj J, Chiba N, et al. (2012) Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. *Immunity* 36: 401-414.
37. Furda AM1, Marrangoni AM, Lokshin A, Van Houten B (2012) Oxidants and not alkylating agents induce rapid mtDNA loss and mitochondrial dysfunction. *DNA Repair (Amst)* 11: 684-692.
38. Shokolenko I1, Venediktova N, Bochkareva A, Wilson GL, Alexeyev MF (2009) Oxidative stress induces degradation of mitochondrial DNA. *Nucleic Acids Res* 37: 2539-2548.
39. Bogenhagen DF1, Rousseau D, Burke S (2008) The layered structure of human mitochondrial DNA nucleoids. *J BiolChem* 283: 3665-3675.
40. Kaufman BA1, Durisic N, Mativetsky JM, Costantino S, Hancock MA, et al. (2007) The mitochondrial transcription factor TFAM coordinates the assembly of multiple DNA molecules into nucleoid-like structures. *MolBiol Cell* 18: 3225-3236.
41. Iyer SS1, He Q, Janczy JR, Elliott EI, Zhong Z, et al. (2013) Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. *Immunity* 39: 311-323.
42. Chu CT1, BayÄ±r H2, Kagan VE3 (2014) LC3 binds externalized cardiolipin on injured mitochondria to signal mitophagy in neurons: implications for Parkinson disease. *Autophagy* 10: 376-378.
43. Park S1, Juliana C, Hong S, Datta P, Hwang I, et al. (2013) The mitochondrial antiviral protein MAVS associates with NLRP3 and regulates its inflammasome activity. *J Immunol* 191: 4358-4366.
44. Subramanian N1, Natarajan K, Clatworthy MR, Wang Z, Germain RN (2013) The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. *Cell* 153: 348-361.

45. Ichinohe T1, Yamazaki T, Koshiba T, Yanagi Y (2013) Mitochondrial protein mitofusin 2 is required for NLRP3 inflammasome activation after RNA virus infection. *ProcNatlAcadSci U S A* 110: 17963-17968.
46. Lee HK1, Song JH, Shin CS, Park DJ, Park KS, et al. (1998) Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus. *Diabetes Res ClinPract* 42: 161-167.
47. Ritov VB, Menshikova EV, Azuma K, Wood R, Toledo FG, et al. (2010) Deficiency of electron transport chain in human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity. *Am J PhysiolEndocrinolMetab*. 298: E49-58.
48. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat Genet*. 34: 267-273.
49. Patti ME1, Butte AJ, Crunkhorn S, Cusi K, Berria R, et al. (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. *ProcNatlAcadSci U S A* 100: 8466-8471.
50. Kadowaki T1, Kadowaki H, Mori Y, Tobe K, Sakuta R, et al. (1994) A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. *N Engl J Med* 330: 962-968.
51. Lindroos MM1, Borra R, Mononen N, Lehtimäki T, Virtanen KA, et al. (2011) Mitochondrial diabetes is associated with insulin resistance in subcutaneous adipose tissue but not with increased liver fat content. *J Inherit Metab Dis* 34: 1205-1212.
52. Bannwarth S, Procaccio V, Lebre AS, Jardel C, Chaussonnet A, et al. (2013) Prevalence of rare mitochondrial DNA mutations in mitochondrial disorders. *J Med Genet*. 50:704-714.
53. Schaefer AM1, McFarland R, Blakely EL, He L, Whittaker RG, et al. (2008) Prevalence of mitochondrial DNA disease in adults. *Ann Neurol* 63: 35-39.
54. Feinstein R1, Kanety H, Papa MZ, Lunenfeld B, Karasik A (1993) Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. *J BiolChem* 268: 26055-26058.
55. Hotamisligil GS1, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. *Science* 259: 87-91.
56. Lee YS1, Li P, Huh JY, Hwang IJ, Lu M, et al. (2011) Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. *Diabetes* 60: 2474-2483.
57. Shoelson SE1, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. *J Clin Invest* 116: 1793-1801.
58. Henriksbo BD1, Lau TC1, Cavallari JF1, Denou E1, Chi W1, et al. (2014) Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. *Diabetes*.
59. Vandanmagsar B1, Youm YH, Ravussin A, Galgani JE, Stadler K, et al. (2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. *Nat Med* 17: 179-188.
60. Mirza RE1, Fang MM, Weinheimer-Haus EM, Ennis WJ, Koh TJ (2014) Sustained inflammasome activity in macrophages impairs wound healing in type 2 diabetic humans and mice. *Diabetes* 63: 1103-1114.
61. Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, et al. (2003) Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac Myocytes. *Circulation* 107: 1418-1423.
62. Samavati L, Lee I, Mathes I, Lottspeich F, Huttemann M (2008) Tumor necrosis factor alpha inhibits oxidative phosphorylation through tyrosine phosphorylation at subunit I of cytochrome c oxidase. *J Biol Chem*. 283: 21134-21144.
63. Vadrot N1, Ghanem S, Braut F, Gavrilescu L, Pilard N, et al. (2012) Mitochondrial DNA maintenance is regulated in human hepatoma cells by glycogen synthase kinase 3 β and p53 in response to tumor necrosis factor α . *PLoS One* 7: e40879.
64. Suliman HB1, Welty-Wolf KE, Carraway MS, Schwartz DA, Hollingsworth JW, et al. (2005) Toll-like receptor 4 mediates mitochondrial DNA damage and biogenic responses after heat-inactivated E. coli. *FASEB J* 19: 1531-1533.
65. Remels AH1, Gosker HR, Schrauwen P, Hommelberg PP, Sliwinski P, et al. (2010) TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia? *FASEB J* 24: 5052-5062.
66. Wang M, Wang XC, Zhang ZY, Mou B, Hu RM (2010) Impaired mitochondrial oxidative phosphorylation in multiple insulin-sensitive tissues of humans with type 2 diabetes mellitus. *J Int Med Res* 38:769-781.
67. Yuzefovych LV1, Musiyenko SI, Wilson GL, Racheck LI (2013) Mitochondrial DNA damage and dysfunction, and oxidative stress are associated with endoplasmic reticulum stress, protein degradation and apoptosis in high fat diet-induced insulin resistance mice. *PLoS One* 8: e54059.
68. Pospisilik JA1, KnaufC, Joza N, Benit P, Orthofer M, et al. (2007) Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. *Cell* 131: 476-491.
69. Park SY1, Lee W (2007) The depletion of cellular mitochondrial DNA causes insulin resistance through the alteration of insulin receptor substrate-1 in rat myocytes. *Diabetes Res ClinPract* 77 Suppl 1: S165-171.
70. Ryu HS1, Park SY, Ma D, Zhang J, Lee W (2011) The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. *PLoS One* 6: e17343.
71. Amuthan G1, Biswas G, Zhang SY, Klein-Szanto A, Vijayasathy C, et al. (2001) Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. *EMBO J* 20: 1910-1920.
72. Owusu-Ansah E1, Yavari A, Mandal S, Banerjee U (2008) Distinct mitochondrial retrograde signals control the G1-S cell cycle checkpoint. *Nat Genet* 40: 356-361.
73. Garbett K1, Ebert PJ, Mitchell A, Lintas C, Manzi B, et al. (2008) Immune transcriptome alterations in the temporal cortex of subjects with autism. *Neurobiol Dis* 30: 303-311.
74. Ziats MN, Rennert OM (2011) Expression profiling of autism candidate genes during human brain development implicates central immune signaling pathways. *PLoS One*. 6:e24691.
75. Wei H1, Zou H, Sheikh AM, Malik M, Dobkin C, et al. (2011) IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. *J Neuroinflammation* 8: 52.
76. Ashwood P1, Wakefield AJ (2006) Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. *J Neuroimmunol* 173: 126-134.
77. Molloy CA1, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K, et al. (2006) Elevated cytokine levels in children with autism spectrum disorder. *J Neuroimmunol* 172: 198-205.
78. Franchi L1, Eigenbrod T, Núñez G (2009) Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. *J Immunol* 183: 792-796.
79. Tang G1, Gutierrez Rios P, Kuo SH, Akman HO, Rosoklija G, et al. (2013) Mitochondrial abnormalities in temporal lobe of autistic brain. *Neurobiol Dis* 54: 349-361.
80. Heneka MT1, Kummer MP, Stutz A, Delekate A, Schwartz S, et al. (2013) NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. *Nature* 493: 674-678.
81. Bracey NA, Beck PL, Muruve DA, Hirota SA, Guo J, et al. (2013) The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta. *Exp Physiol*. 98:462-472.
82. Mathew A, Lindsley TA, Sheridan A, Bhoiwala DL, Hushmendy SF, et al. (2012) Degraded mitochondrial DNA is a newly identified subtype of the damage associated molecular pattern (DAMP) family and possible trigger of neurodegeneration. *J Alzheimers Dis*. 30:617-627.

83. Chaung WW1, Wu R, Ji Y, Dong W, Wang P (2012) Mitochondrial transcription factor A is a proinflammatory mediator in hemorrhagic shock. *Int J Mol Med* 30: 199-203.
84. Simmons JD1, Lee YL, Mulekar S, Kuck JL, Brevard SB, et al. (2013) Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects. *Ann Surg* 258: 591-596.
85. Sun S, Sursal T, Adibnia Y, Zhao C, Zheng Y, et al. (2013) Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways. *PLoS One*. 8:e59989.